Folia Medica Indonesiana
ISSN 0303-7932
Vol. 51 / No. 2 / Published : 2015-04
Order : 2, and page :86 - 90
Related with : Scholar Yahoo! Bing
Original Article :
Comparison of the effect of statin types on the reduction of lipid profile and hs-crp inflammatory marker in diabetics with dyslipidemia
Author :
- Nur Palestin Ayumuyas*1
- Debra Dorotea*2
- Budi Suprapti*3
- Sony Wibisono*4
- Dosen Fakultas Farmasi
- Dosen Fakultas Farmasi
- Dosen Fakultas Farmasi
- Dosen Fakultas Kedokteran
Abstract :
Elevated inflammation marker C-reactive protein (CRP) is commonly associated with cardiovascular disease. Statins inhibit theenzyme HMG-CoA reductase, which is required for cholesterol biosynthesis and might also exert pleiotropic effects so that beneficialin the prevention of cardiovascular disease. All statins have the same mechanism of action but different in chemical structures,pharmacokinetic profiles, and lipid reducing efficacy. The objective of this study was to compare the efficacy of two statins,atorvastatin and simvastatin to reduce the lipid profiles and inflammation marker Hs-CRP in patient diabetes mellitus type 2 withdyslipidemic. This was a prospective cohort observational study of 18 diabetes dyslipidemia patient taking either simvastatin 20 mg(n = 11 patient) and atorvastatin 10 mg (n = 7 patient) for about 6 weeks. The efficacy of therapy measured by lipid profiles (totalcholesterol, LDL-C and triglyceride) and inflammation marker Hs-CRP. After 6 weeks therapy, lipid profile and inflammationmarker Hs-CRP pre and post therapy of either taking simvastatin 20 mg or atorvastatin 10 mg did not shown the significancedifferent (p > 0.05). There were also no significance different in lipid profiles between the two groups. In the other hand, theinflammation marker Hs-CRP serum of atorvastatin group significantly decrease compared to simvastatin group (p < 0.05). Inconclusion, there were no different in reducing lipid profiles (total cholesterol, LDL-C, and triglyceride) in either patient takingatorvastatin 10 mg or simvastatin 20 mg after six weeks therapy. Atorvastatin decrease the inflammation marker Hs-CRP serumsbetter than simvastatin. (FMI 2015;51:86-90)
Keyword :
simvastatin, atorvastatin, lipid, Hs-CRP, diabetes,
References :
Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S ,(2001) Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels 103, 1933-1935 : Circulation
Kumar A, Singh V ,(2010) Atherogenic dyslipidemia and diabetes mellitus: what’s new in the management area? 6, 665- 669 : Vascular Health and Risk Management
Archive Article
Cover Media | Content |
---|---|
![]() Volume : 51 / No. : 2 / Pub. : 2015-04 |
|